Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA-125 level

被引:37
作者
Obeidat, B
Latimer, J
Crawford, R
机构
[1] Jordan Univ Sci & Technol, Dept Obstet & Gynaecol, JO-21110 Irbid, Jordan
[2] Cambridge Canc Ctr, Cambridge, England
关键词
epithelial ovarian cancer; cytoreduction; serum CA-125; FIGO stage III ovarian carcinoma; receiver operating characteristic curve;
D O I
10.1159/000076236
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
The aim of this study was to determine the ability of preoperative serum CA-125 levels to predict optimal cytoreduction in patients with stage III epithelial ovarian cancer. A retrospective review was made of the records of 40 patients with FIGO stage III ovarian carcinoma who underwent primary cytoreductive surgery. A receiver operating characteristic (ROC) curve was used to determine the most useful CA-125 level in predicting optimal versus suboptimal tumour cytoreduction. Twenty-two (55%) patients were optimally cytoreduced ( residual disease less than or equal to 1 cm). A preoperative serum CA-125 level of 500 U/ml was found to be the value with the most predictive power. Optimal cytoreduction was obtained in 16 of the 21 cases (76%) with a CA-125 < 500 U/ml compared to only 6 of the 19 cases (32%) with a CA-125 >500 U/ml. At this threshold, preoperative serum CA-125 level was able to predict optimal versus suboptimal cytoreduction with a sensitivity of 72%, specificity of 73%, positive predictive value of 68%, and negative predictive value of 76%. In the management of patients with advanced epithelial ovarian carcinoma, preoperative serum CA-125 level may help to predict optimal primary cytoreduction and to identify candidates for alternative approaches other than traditional primary cytoreductive surgery, such as neoadjuvant chemotherapy. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:153 / 156
页数:4
相关论文
共 15 条
[1]   Preoperative prediction of optimal resectability in advanced ovarian cancer using CA-125 [J].
Berek, JS .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :225-226
[2]   The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma [J].
Chi, DS ;
Venkatraman, ES ;
Masson, V ;
Hoskins, WJ .
GYNECOLOGIC ONCOLOGY, 2000, 77 (02) :227-231
[3]  
Geisler JP, 1996, J REPROD MED, V41, P140
[4]  
HACKER NF, 1983, OBSTET GYNECOL, V61, P413
[5]   THE EFFECT OF DIAMETER OF LARGEST RESIDUAL DISEASE ON SURVIVAL AFTER PRIMARY CYTOREDUCTIVE SURGERY IN PATIENTS WITH SUBOPTIMAL RESIDUAL EPITHELIAL OVARIAN-CARCINOMA [J].
HOSKINS, WJ ;
MCGUIRE, WP ;
BRADY, MF ;
HOMESLEY, HD ;
CREASMAN, WT ;
BERMAN, M ;
BALL, H ;
BEREK, JS .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1994, 170 (04) :974-980
[6]   THE INFLUENCE OF CYTOREDUCTIVE SURGERY ON RECURRENCE-FREE INTERVAL AND SURVIVAL IN SMALL-VOLUME STAGE-III EPITHELIAL OVARIAN-CANCER - A GYNECOLOGIC ONCOLOGY GROUP-STUDY [J].
HOSKINS, WJ ;
BUNDY, BN ;
THIGPEN, JT ;
OMURA, GA .
GYNECOLOGIC ONCOLOGY, 1992, 47 (02) :159-166
[7]  
JACOBS I, 1989, HUM REPROD, V4, P1
[8]   Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [J].
McGuire, WP ;
Hoskins, WJ ;
Brady, MF ;
Kucera, PR ;
Partridge, EE ;
Look, KY ;
ClarkePearson, DL ;
Davidson, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (01) :1-6
[9]   CA125 levels are a weak predictor of optimal cytoreductive surgery in patients with advanced epithelial ovarian cancer [J].
Memarzadeh, S ;
Lee, SB ;
Berek, JS ;
Farias-Eisner, R .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2003, 13 (02) :120-124
[10]   PREOPERATIVE ABDOMINOPELVIC COMPUTED TOMOGRAPHIC PREDICTION OF OPTIMAL CYTOREDUCTION IN EPITHELIAL OVARIAN-CARCINOMA [J].
NELSON, BE ;
ROSENFIELD, AT ;
SCHWARTZ, PE .
JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (01) :166-172